Roquefort Therapeutics (LSE:ROQ) Other Long-Term Liabilities : £0.28 Mil (As of Jun. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Roquefort Therapeutics Other Long-Term Liabilities?

Roquefort Therapeutics's other long-term liabilities for the quarter that ended in Jun. 2024 was £0.28 Mil.

Roquefort Therapeutics's quarterly other long-term liabilities declined from Jun. 2023 (£0.28 Mil) to Dec. 2023 (£0.28 Mil) but then increased from Dec. 2023 (£0.28 Mil) to Jun. 2024 (£0.28 Mil).

Roquefort Therapeutics's annual other long-term liabilities increased from Dec. 2021 (£0.28 Mil) to Dec. 2022 (£0.28 Mil) but then declined from Dec. 2022 (£0.28 Mil) to Dec. 2023 (£0.28 Mil).

Roquefort Therapeutics Other Long-Term Liabilities Historical Data

The historical data trend for Roquefort Therapeutics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Roquefort Therapeutics Other Long-Term Liabilities Chart

Roquefort Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Other Long-Term Liabilities

Roquefort Therapeutics Semi-Annual Data
	Jun21	Jun22	Dec22	Jun23	Dec23	Jun24
Other Long-Term Liabilities	Get a 7-Day Free Trial			-	-	-	-	-

Roquefort Therapeutics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Roquefort Therapeutics Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Roquefort Therapeutics's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Roquefort Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Roquefort Therapeutics PLC (LSE:ROQ) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

85 Great Portland Street, First Floor, London, GBR, W1W 7LT

Website

https://www.roquefortplc.com

Roquefort Therapeutics PLC is engaged in pursuing opportunities to acquire medical biotechnology businesses. Its product portfolio consists of MDK Antibody, MDK Oligo, MDK mRNA, STAT-6 siRNA, and MK Cell. The principal activity of the Company is to develop pre-clinical next-generation medicines focused on hard-to-treat cancers.

Roquefort Therapeutics Headlines

No Headlines